A novel hyperglycaemic clamp for characterization of islet function in humans: Assessment of three different secretagogues, maximal insulin response and reproducibility

European Journal of Clinical Investigation

Volumn 30, Issue 5, 2000, Pages 411-418

  Fritsche, A ^a,b   Stefan, N ^a,b   Hardt, E ^a,b   Schutzenauer S ^a,b   Haring H ^a,b   Stumvoll, Michael ^a,b,c  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b Medizinische Klinik   (Germany)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Arginine; GLP 1; Incretin; Insulin resistance; Insulin secretion; Type 2 diabetes

Indexed keywords

ARGININE; C PEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN;

ARTICLE; CLINICAL TRIAL; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN RESPONSE; MALE; NORMAL HUMAN; PANCREAS FUNCTION; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; VOLUNTEER;

ADULT; ARGININE; BLOOD GLUCOSE; C-PEPTIDE; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDES; GLUCOSE; GLUCOSE CLAMP TECHNIQUE; HUMANS; HYPERGLYCEMIA; INSULIN; INSULIN RESISTANCE; ISLETS OF LANGERHANS; MALE; PEPTIDE FRAGMENTS; PROTEIN PRECURSORS; REPRODUCIBILITY OF RESULTS;

EID: 0034014912     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.2000.00649.x     Document Type: Article

References (38)

1. 1 De Fronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of NIDDM. Diabetes Care 1992;15:318-68.
2. 2 Gerich JE. Metabolic abnormalities in impaired glucose tolerance. Metabolism 1997;46 (Suppl. 1):40-3.
3. 3 Gerich JE. The genetic basis of type 2 diabetes mellitus: impaired insulin secretion versus impaired insulin sensitivity. Endocr Rev 1998;19:491-503.
4. 4 Pimenta W, Kortytkowski M, Mitrakou A, Jenssen T, Yki-Järvinen H, Evron W et al. Pancreatic beta-cell dysfunction as the primary genetic lesion in NIDDM. JAMA 1995;273:1855-61.
5. 5 Thorburn AW, Proietto J. Peripheral tissue glucose uptake is not reduced after an oral glucose load in Southern Italian subjects at risk of developing non-insulin-dependent diabetes mellitus. Metabolism 1999;48:80-5.
6. 6 Van Haeften TW, Dubbeldam S, Zonderland ML, Erkelens DW. Insulin secretion in normal glucose-tolerant relatives of type 2 diabetic subjects. Assessments using hyperglycemic glucose clamps and oral glucose tolerance tests. Diabetes Care 1998;21:278-82.
7. 7 Tattersall R. Maturity-onset diabetes of the young: a clinical history. Diabet Med 1998;15:11-4.
8. 8 Vauhkonen I, Niskanen L, Vanninen E, Kainulainen S, Uusitupa M, Laakso M. Defects in insulin secretion and insulin action in non-insulin-dependent diabetes mellitus are inherited. Metabolic studies on offspring of diabetic probands. J Clin Invest 1998;101:86-96.
9. 9 Yki-Järvinen H. Glucose toxicity. Endocr Rev 1992;13:415-31.
10. 10 Eriksson J, Franssila-Kallunki A, Ekstand A, Saloranta C, Widen E, Shalin C et al. Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus. N Engl J Med 1989;321:337-43.
11. 11 Beck-Nielsen H, Groop LC. Metabolic and genetic characterization of prediabetic states. J Clin Invest 1994;94:1714-21.
12. 12 Volk A, Renn W, Overkamp D, Mehnert B, Maerker E, Jacob S et al. Insulin action and secretion in healthy, glucose tolerant first degree relatives of patients with type 2 diabetes. Influence of body weight. Exp Clin Endocrinol Diabetes 1999;107:140-7.
13. 13 Bergman RN, Phillips LS, Cobelli C. Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and beta-cell glucose sensitivity from the response to intravenous glucose. J Clin Invest 1981;68:1456-67.
14. 14 De Fronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979;237:E214-23.
15. 15 Castillo MJ, Scheen AJ, Lefebvre PJ. Modified glucagon test allowing simultaneous estimation of insulin secretion and insulin sensitivity: application to obesity, insulin-dependent diabetes mellitus, and noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1995;80:393-9.
16. 16 Gjessing HJ, Reinholdt B, Pedersen O. The plasma C-peptide and insulin responses to stimulation with intravenous glucagon and a mixed meal in well-controlled type 2 (non-insulin-dependent) diabetes mellitus: dependency on acutely established hyperglycaemia. Diabetologia 1989;32:858-63.
17. 17 Hosker J, Mathews D, Rudenski A, Burnett M, Darling P, Brown E et al. Continuous infusion of glucose with model assessment: measurement of insulin resistance and B-cell function in man. Diabetologia 1985;28:401-11.
18. 18 Ward WK, Bolgiano DC, McKnight B, Halter JB, Porte D Jr. Diminished B cell secretory capacity in patients with non-insulin-dependent diabetes mellitus. J Clin Invest 1984;74:1318-28.
19. 19 Larsson H, Ahren B. Glucose-dependent arginine stimulation test for characterization of islet function: studies on reproducibility and priming effect of arginine. Diabetologia 1998;41:772-7.
20. 20 Orskov C, Wettergren A, Holst JJ. Biological effects and metabolic rates of glucagonlike peptide-1, 7-36 amide and glucagonlike peptide-1, 7-37 in healthy subjects are indistinguishable. Diabetes 1993;42:658-61.
21. 21 Ahren B, Larsson H, Holst JJ. Effects of glucagon-like-peptide-1 on islet function and insulin senstivity in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1997;82:473-8.
22. 22 Van Haeften TW, Boonstra E, Veneman TF, Gerich JE, Van der Veen EA. Dose-response characteristics for glucose-stimulated insulin release in man and assessment of influence of glucose on arginine-stimulated insulin release. Metabolism 1990;39:1292-9.
23. 23 Bonnevie-Nielsen V, Skovgaard LT, Lernmark A. β-cell function relative to islet volume and hormone content in the isolated perfused mouse pancreas. Endocrinology 1983;112:1049-56.
24. 24 Sonksen PH, Tompkins CV, Srivastava MC, Nabarro JD. A comparative study on the metabolism of human insulin and porcine proinsulin in man. Clin Sci Mol Med 1973;45:633-54.
25. 25 Rossell R, Gomis R, Casamitjana R, Segura R, Vilardell E, Rivera F. Reduced hepatic insulin extraction in obesity: relationship with plasma insulin levels. J Clin Endocrinol Metab 1983;56:608-11.
26. 26 Savage PJ, Flock EV, Mako ME, Blix PM, Rubenstein AH, Bennett PH. C-Peptide and insulin secretion in Pima Indians and Caucasians: constant fractional hepatic extraction over a wide range of insulin concentrations and in obesity. J Clin Endocrinol Metab 1979;48:594-8.
27. 27 Bardet S, Pasqual C, Maugendre D, Remy J-P, Charbonnel B, Sai P. Inter and intraindividual variability of acute insulin response during intravenous glucose tolerance tests. Diabete Metab 1989;15:224-32.
28. 28 Unger RH, Orci L. Glucagon. In: Kahn R, Weir GC, editors. Joslin's Diabetes Mellitus. Lea & Febiger:Malvern, PA, USA;1994.p. 163-76.
29. 29 Freyse EJ, Becher T, El Hag O, Knospe S, Goke B, Fischer U. Blood glucose lowering and glucagonostatic effects of glucagon-like peptide I in insulin-deprived diabetic dogs. Diabetes 1997;46:824-8.
30. 30 Larsson H, Berglund G, Ahren B. Glucose modulation of insulin and glucagon secretion is altered in impaired glucose tolerance. J Clin Endocrinol Metab 1995;80:1778-82.
31. 31 Mitrakou A, Kelley D, Mokan M, Veneman T, Pangburn T, Reilly T et al. Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N Engl J Med 1992;326:22-9.
32. 32 Elbein SC, Hasstedt SJ, Wegner K, Kahn SE. Heritability of pancreatic beta-cell function among nondiabetic Caucasian familial type 2 diabetic kindreds. J Clin Endocrinol Metab 1999;84:1398-403.
33. 33 Polonsky K. The beta-cell in diabetes: from molecular genetics to clinical research. Diabetes 1995;44:705-17.
34. 34 Drucker DJ. Glucagon-like peptides. Diabetes 1998;47:159-69.
35. 35 Matsuda A, Kuzuya T. The prevalence of low insulin responders to oral glucose load among groups with various patterns of family history of diabetes. Diabet Med 1996;13:S59-62.
36. 36 Herman WH, Fajans SS, Ortiz FJ, Smith MJ, Sturis J, Bell GI et al. Abnormal insulin secretion not insulin resistance, is the genetic or primary defect of MODY in the RW pedigree. Diabetes 1994;43:40-6.
37. 37 Withers DJ, Gutierrez JS, Towery H, Burks DJ, Ren JM, Previs S et al. Disruption of IRS-2 causes type 2 diabetes in mice. Nature 1998;391:900-4.
38. 38 Bernal D, Almind K, Yenush L, Ayoub M, Zhang Y, Rosshani L et al. Insulin receptor substrate-2 amino acid polymorphisms are not associated with random type 2 diabetes among Caucasians. Diabetes 1998;47:976-9.